SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is experiencing a parabolic surge, fueled by escalating industrial demand for silver in new technologies and anticipation of China's upcoming export restrictions. Community discussion highlights a potential short squeeze and belief that long-term price suppression is ending, though some anticipate a sharp correction after such an aggressive run.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending with gold prices reaching new all-time highs, driven by escalating geopolitical tensions, a weakening dollar, and widespread anticipation of significant Fed monetary easing. The community is actively debating whether this surge reflects a "currency reset" and a flight to real assets amid an over-indebted global environment, or if it signals an overheated market due for a correction, with many noting a rotation of investment capital from cryptocurrencies into precious metals.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending due to its real-world asset integration via Cocky Wings LLC, which is actively generating revenue and performing token buybacks, enhancing liquidity. The community on Cardano is highly engaged, discussing its new DApp, passive earning opportunities in the 'Arena,' and its long-term potential as a utility-backed meme coin.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

ASPC is experiencing extreme price volatility and massive trading volume, sparking widespread community discussion around a potential short squeeze. Traders are actively debating its rapid movements, with some anticipating significant further momentum while others caution about the inherent risks of such speculative, low-float plays. The overall sentiment is sharply divided between those betting on continued upside and those warning of a pump-and-dump dynamic.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG CRYPTO is trending due to significant community discussion around its unique position as a Bitcoin-native memecoin, particularly on the Runes protocol. Bulls are highlighting recent strategic acquisitions by C2 Blockchain, which has notably expanded its $DOG treasury. The "DOG Army" expresses strong conviction, positioning $DOG as a contender to "drop the E" and become a dominant meme asset on the secure Bitcoin network.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

Sprott Physical Silver Trust (PSLV) is experiencing significant attention as the community widely discusses a powerful silver squeeze, driven by a growing structural supply deficit and surging industrial demand across critical sectors. Many believe long-standing market suppression is breaking, potentially leading to a historic price discovery phase. Investor conversations emphasize the intrinsic value of physical silver as a hedge against broader economic uncertainties.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Trust - ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is currently trending amidst widespread community belief in a historic silver breakout, driven by strong industrial demand, geopolitical instability, and anticipation of central bank dovish pivots. Investors are actively discussing extreme upside targets for silver and its leveraged ETFs, with many highlighting its undervalued status relative to gold and expressing a "silver squeeze" narrative.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending following the landmark FDA approval of YARTEMLEA, establishing it as the first and only approved therapy for transplant-associated thrombotic microangiopathy (TA-TMA) in both adult and pediatric patients. This pivotal de-risking event, coupled with its strengthened financial position from a major partnership, has fueled community excitement regarding commercialization potential, anticipated analyst upgrades, and significant upside ahead of its upcoming conference call.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

Universe Pharmaceuticals (UPC) is trending due to a massive surge in trading volume and significant price volatility, driven by its extremely low public float. Community sentiment is highly polarized, with some anticipating a substantial short squeeze and advocating for holding shares for significant gains, while others caution it's a 'pump and dump' given its status as a China-based micro-cap. Discussion often highlights the company's strong cash position relative to its market capitalization, fueling speculation of high intrinsic value and potential for rapid upward movement if buying pressure continues.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending amid significant trading volume, driven by renewed investor interest in its compute-in-memory (CIM) APU technology following sector developments. The community is actively debating the company's potential as a disruptive force in edge AI, with discussions centering on its low-power Gemini chips for defense, drone, and satellite applications, including partnerships. Anticipation for upcoming multi-modal large language model benchmarks is also fueling conversation around GSIT's unique position in the evolving AI hardware landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know

AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.

<ul class="summary-bullets"><li>Fitch believes companies with portfolios focused on oncology, immunology, rare diseases, vaccines and metabolic or weight‑management therapies are likely to outgrow the market.&nbsp;</li><li>The firm deems policy risk, particularly regarding drug pricing, as high.&nbsp;</li><li>Fitch now expects global pharma revenue growth to be around 3.2% in 2026.&nbsp;</li></ul><p>Fitch Ratings said on Tuesday that it expects mid-single-digit growth in global medicines spending in 2026, supported by an aging population and broadening access to healthcare.</p><p>The global pharma sector’s operating environment will remain stable supporting a ‘neutral’ outlook, Fitch Ratings <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fitchratings.com/research/corporate-finance/global-pharmas-2026-demand-growth-resilient-a-test-year-for-margins-23-12-2025">said</a>, while adding that companies with portfolios focused on oncology, immunology, rare diseases, vaccines and metabolic or weight‑management therapies are likely to outgrow the market.</p><h2 class="st-heading-2">Policy Risks</h2><p>Fitch, however, flagged risks including policy uncertainty testing operating profitability. Fitch deems policy risk, particularly regarding drug pricing, as high.</p><p>“In the US, the Most Favoured Nation pricing framework, potential import tariffs and evolving pharmacy benefit manager access dynamics are likely to increase pricing dispersion and cost volatility in 2026,” it said. “Issuers with diversified portfolios, domestic manufacturing options and inventory flexibility should preserve rating headroom despite policy volatility.”</p><p>Fitch now expects global pharma revenue growth to be around 3.2% in 2026, below the 5.3% expected in 2025. The base case for revenue growth is underpinned by innovation and volume increases in chronic and specialty categories, it said. Players with specialized therapeutic depth and broad modality exposure are better positioned to sustain above-market trajectories, Fitch added.</p><h2 class="st-heading-2">M&amp;A Activity In 2026</h2><p>The firm now sees merger and acquisition activity to remain elevated in 2026, extending the 2025 rebound in biotech dealmaking that outdid 2024 levels. It also expects a sustained rise in capital expenditure as companies regionalize manufacturing and invest in complex biologics and cell and gene platforms.</p><h2 class="st-heading-2">Trump’s Most Favored Pricing Deals</h2><p>Last week, U.S. President Trump<a href="https://stocktwits.com/news-articles/markets/equity/trump-strikes-new-drug-price-deals-with-roche-novartis-merck-and-other-pharma-giants/cLe0duBREtP"> announced</a> nine new agreements with pharma companies to lower prescription drug prices for Americans to levels paid in other developed nations. Overall, 14 pharma companies have now inked similar deals with the administration in return for pharma tariff reprieve and expedited drug application reviews including Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Pfizer, Eli Lilly and Sanofi.</p><p>The S&amp;P Pharmaceuticals Select Industry Index has gained about 31% this year while the Dow Jones U.S. Pharmaceuticals Index gained over 24%.</p><p>Large-cap pharma stocks like Eli Lilly, Johnson &amp; Johnson, and Merck have all gained single to double digit stock growth this year while Pfizer fell 6%.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-confirms-death-of-patient-enrolled-in-hemophilia-drug-study/cLepu4KREHO">Pfizer Confirms Death Of Patient Enrolled In Hemophilia Drug Study</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Young female scientist working in laboratory (Representative image courtesy of Solskin via Getty Images)

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk

The firm also expects merger and acquisition activity in the sector to remain elevated in 2026. 

Equity

GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages

Shares of GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) have been given a consensus recommendation of "Hold" by the eight research firms that are covering the stock, MarketBeat.com reports. Two...

Wendy Becker Acquires 441 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK - Get Free Report) insider Wendy Becker purchased 441 shares of the business's stock in a transaction that occurred on Friday, December 19th. The shares were bought at an average...

GSK (LON:GSK) Insider Purchases 7,977.69 in Stock

GSK plc (LON:GSK - Get Free Report) insider Wendy Becker bought 441 shares of the stock in a transaction on Friday, December 19th. The stock was purchased at an average cost of GBX 1,809 per share...

Insider Buying: GSK (LON:GSK) Insider Purchases 1,650 Shares of Stock

GSK plc (LON:GSK - Get Free Report) insider Jonathan Symonds purchased 1,650 shares of the company's stock in a transaction dated Monday, December 22nd. The stock was purchased at an average cost of...

US Medicaid Program Will Hit Swiss Wallets Hard, Roche CEO Says

Roche CEO predicts higher drug costs in Switzerland due to U.S. government's deals with pharmaceutical companies.read more...

Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals

Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.

Samsung Biologics To Acquire GSK's Rockville Facility For US$280 Mln

(RTTNews) - Samsung Biologics (207940.KS) announced that its wholly owned U.S. subsidiary, Samsung Biologics America, will acquire 100% of Human Genome Sciences from GSK (GSK, GSK.L) for US$280...

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Current Price	$49.08
Prev Close	$48.96
Open	$48.97
Dividend Yield	4.53%
50-Day Moving Average	$47.02
Beta	0.27
Avg. Volume	4.66M
PE Ratio	13.77

52-Week High	$49.44
52-Week Low	$31.72
Market Capitalization	$98.78B
EPS (Annual)	$1.61
Price to Book	4.53
Revenue Per Employee	$584,193.84
Enterprise Value/EBITDA	N/A

GSK
Glaxosmithkline plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GSK News

GSKGlaxosmithkline plc - ADR